The present disclosure relates to MMP8 inactivating antigen binding proteins, preferably antigen binding proteins comprising an amino acid sequence that comprises (4) framework regions and (3) complementary determining regions it relates further to the use of such antigen binding proteins to treat inflammation, such as but not limited to systemic inflammatory response syndrome, sepsis, LPS induced inflammation, renal ischemia/reperfusion injury, ventilation induced lung injury, periodontal inflammation, rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, lyme arthritis and osteoarthritis.
